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Background: ME-401, a potent and selective oral PI3kδ inhibitor,
is being evaluated in a Phase 1b study in patients (pts) with R/R
B-cell malignancies (NCT02914938). 70 pts were treated as of
January 2019 and we report here results in pts with FL and
CLL/SLL.
Methods: Adult pts with ECOG performance status ≤2, no prior PI3K
therapy, and progression of disease (POD) after ≥1 prior therapy were
initially enrolled in a dose escalation phase (60-180 mg) then in 60 mg
expansion cohorts as monotherapy or in combination with rituximab
(375 mg/m² x 8 doses in 6 months). ME-401 was given initially on a
daily continuous schedule (CS) until POD or unacceptable toxicity.
Patients on CS were switched to an intermittent schedule (IS) on days
1-7 of a 28-day cycle in Cycle 3 (n = 20) or in Cycles ≥4 (n = 18) of
CS. Toxicity on CS was managed by switch to IS and POD on IS was
managed by switch to CS.
Results: 61 pts, 48 with FL and 13 with CLL/SLL received ME-401
alone (n = 48) or with rituximab (n = 13). Median age 65 yrs. (range:
38-81), median prior therapies 2 (range: 1-10), 33 pts had ≥2 prior ther-
apies, and 25 FL pts were POD24. In CLL/SLL pts, IgVH was unmutated
in 7, mutated in 2, and not evaluated in 4. 39 pts (64%) remain on ther-
apy with a median follow-up of 12.3 months (range: 1.6-25.1) and
22 pts discontinued: 9 POD, 5 adverse events (AEs), 5 withdrew con-
sent, and 3 were referred to stem cell transplant in CR. Delayed
(i.e., Cycle >2) grade 3 immune related AEs (irAEs), primarily dia-
rrhea/colitis and rash, were reported in 13/41 pts (31.7%) on CS and
2/20 pts (10%) who had switched to IS in Cycle 3, with irAEs noted
15 and 18 days after switch to IS. 6 pts with grade 3 irAEs had a drug
holiday and corticosteroid therapy then resumed ME-401 on IS without
recurrence of the irAE. Objective responses were achieved in 33/43
evaluable FL pts (77%) and 11/11 evaluable CLL/SLL pts (100%). In FL,
response rate was 77% with ME-401 alone (including 29% CR by
Lugano criteria), 78% with ME-401 plus rituximab, 91% in POD24, and
75% in pts who had ≥2 prior therapies. Of 38 pts switched to IS,
33 (87%) remain on therapy (median: 14.5 months), 26 on IS and 7 who
switched back to CS due to POD on IS, 3 pts discontinued due to per-
sistent POD after switch to CS, and 2 pts withdrew.
Conclusions: ME-401 achieves a high rate of durable responses in
R/R FL and CLL/SLL. IS appears to reduce the incidence of irAEs and
maintain responses. POD on IS can be successfully retreated by rever-
ting to CS. A global study is enrolling pts with R/R FL randomized to
ME-401 by IS or CS after 2 cycles of CS, with switch to IS for irAEs
and switch to CS if POD on IS (NCT03768505).
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TABLE 1
Dosing
Schedule
No. of
Pts
No. (%) of
irAEs
No. Efficacy
Evaluable Pts
No. (%)
CR+PR
CS or CS! IS
in Cycles ≥4
41 13 (31.7%) 34 28 (82%)
CS! IS in
Cycle 3
20 2 (10%) 20 16 (80%)
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Background: AFM13 is a bispecific, tetravalent NK cell-engaging anti-
body construct binding to CD30 on Hodgkin Lymphoma (HL) cells and
CD16A on NK cells 1^. Pembrolizumab is a PD-1 blocking antibody
that induces high response rates in patients (pts) with relapsed or
refractory HL (RRHL) 2^. AFM13 has shown clinical activity in pts with
RRHL in a Phase 1 study 3^. Preclinical data of the combination of
AFM13 with PD-1 inhibition suggest synergism 4^.
Methods: This Phase 1b dose escalation/extension study is evaluat-
ing the safety, tolerability and preliminary efficacy of the combina-
tion of AFM13 with pembrolizumab as salvage therapy after failure
of standard therapies including brentuximab vedotin (BV) in pts with
HL (NCT02665650). Pts receive escalating doses of AFM13 in com-
bination with pembrolizumab following the classical 3+3 design.
Response assessment is performed every 12 weeks by PET/CT
according to the Lugano Classification 5^. Data as of February
12, 2019 are presented.
Results: All thirty pts have been enrolled. The median age is 34 years
(18-73), with a median of 4 (3-7) prior lines of therapy. All pts have
failed standard treatments including BV and 43% had BV as their lat-
est therapy. Thirty seven percent have undergone prior autologous
stem cell transplantation. Twelve pts were enrolled into the dose
escalation cohorts and 18 into the Extension Cohort. All 30 pts com-
pleted the dose limiting toxicity (DLT) observation period. No DLTs
occurred in Cohorts 1/2, one DLT occurred in Cohort 3 (missed ≥25%
of AFM13 during the DLT period) and one DLT occurred in the Exten-
sion Cohort (Grade (G)4 infusion-related reaction (IRR)). Adverse
Events were mainly G1/G2 and included IRRs (87%), rash (30%), nau-
sea (23%), pyrexia (23%), and diarrhea (20%). G3/4 AEs included IRRs
(13%), elevated aspartate aminotransferase (3%), gastritis (3%), hypo-
tension (3%), nausea (3%), neutropenia (3%), and vomiting (3%).
Included in the efficacy analysis were the best response from all
30 patients. The best overall response rate (ORR) and complete
response (CR) rate for pts treated at the dose and schedule chosen for
expansion (n=24; Cohort 3 and Extension Cohort) were 88% and 46%
by independent assessment. Investigator assessment resulted in an
ORR of 88% and CR rate of 42% for these pts. Estimated 6-month
PFS rate at the highest treated dose level was 77%. Longer term fol-
low up results will be presented at the meeting.
Conclusions: The combination of AFM13 and pembrolizumab is well-
tolerated with most AEs mild to moderate in nature. The ORR of 88%
compares favorably to the historical data of pembrolizumab in a simi-
lar RRHL population, with the CR rates of 42% and 46% by local and
independent assessment, respectively, approximately doubling that of
pembrolizumab (CR rates 22-25%) 2^.
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Introduction: PTCL exhibit pervasive dysfunction of epigenetic opera-
tions. This may be a targetable vulnerability, as demonstrated by the
single-agent activity of histone deacetylase inhibitors (HDACi) and
hypomethylating agents (HMA). We previously showed marked syner-
gism between HDACi and HMA in T-cell lymphoma lines, accompa-
nied by the modulation of >900 unique genes with the combination,
but not the single agents. In a recently completed phase-1 study we
observed encouraging activity of combined oral 5-azacytidine (AZA)
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